logo

For the Inventor, By the Inventor

Arlington, MA, United States of America

Mark A Tracy

USPTO Granted Patents = 23 

Average Co-Inventor Count = 3.1

ph-index = 16

Forward Citations = 1,317(Granted Patents)


Location History:

  • Nampa, ID (US) (1996)
  • Arlington, MA (US) (1997 - 2013)

Company Filing History:

goldMedal19 out of 46 
 
Alkermes Controlled Therapeutics, Inc.
 patents
silverMedal1 out of 30 
 
Civitas Therapeutics, Inc.
 patents
bronzeMedal1 out of 1 
 
Alkermas Controlled Therapeutics, Inc.
 patent
4. 2 out of 832,718 
Other
 patents

Years Active: 1996-2013

Loading Chart...
23 patents (USPTO):Explore Patents
1. 8614255 - Pulmonary pharmaceutical formulations (2013-12-24),
2. 7282216 - Biocompatible polymer blends and uses thereof (2007-10-16),
3. 7097857 - Methods and compositions for the targeted delivery of biologically active agents (2006-08-29),
4. 6780434 - Controlled release of metal cation-stabilized interferon (2004-08-24),
5. 6749866 - Modulated release from biocompatible polymers (2004-06-15),
6. 6719970 - Method of generating cartilage (2004-04-13),
7. 6713087 - Method of producing submicron particles of a labile agent and use thereof (2004-03-30),
8. 6565888 - Methods and compositions for the targeted delivery of biologically active agents (2003-05-20),
9. 6514533 - Device for the sustained release of aggregation-stabilized, biologically active agent (2003-02-04),
10. 6465425 - Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins (2002-10-15),
11. 6455074 - Methods for fabricating polymer-based controlled release devices (2002-09-24),
12. 6444223 - Method of producing submicron particles of a labile agent and use thereof (2002-09-03),
13. 6428815 - Method of producing sub-micron particles of biologically active agents and uses thereof (2002-08-06),
14. 6379701 - Controlled release of metal cation-stabilized interferon (2002-04-30),
15. 6368630 - Modulated release from biocompatible polymers (2002-04-09),

Title: Mark A. Tracy: Innovator in Pharmaceutical Formulations

Introduction

Mark A. Tracy is a prominent inventor based in Arlington, MA, USA, known for his significant contributions to the field of pharmaceutical formulations. With an impressive portfolio of 23 patents, Tracy's work focuses on enhancing drug delivery methods, particularly for respiratory treatments.

Latest Patents

Tracy's latest innovations include two notable patents. The first patent, "Pulmonary Pharmaceutical Formulations," addresses improved pharmaceutical formulations designed for pulmonary delivery, boasting enhanced chemical and physical stability of therapeutic agents. This invention comprises biocompatible particles that include an active agent and hydrogenated starch hydrosylate (HSH), significantly improving prior art formulations. The second patent, titled "Biocompatible Polymer Blends and Uses Thereof," outlines a series of novel polymers created by blending hydrophobic biocompatible, biodegradable polymers with specific properties. This invention further encompasses a process for developing sustained release compositions that efficiently deliver biologically active agents to patients.

Career Highlights

Throughout his career, Mark A. Tracy has worked with various esteemed organizations, including Alkermes Controlled Therapeutics, Inc. His experience in the pharmaceutical industry has been instrumental in guiding his innovative research and development efforts.

Collaborations

Tracy’s work has also involved collaboration with notable professionals such as Howard Bernstein and M Amin Khan. These partnerships have fostered groundbreaking advancements in pharmaceutical formulations and drug delivery systems, amplifying the impact of his inventions.

Conclusion

Mark A. Tracy's dedication to developing innovative pharmaceutical solutions highlights his role as a key inventor in the industry. His contributions, particularly in pulmonary drug delivery and polymer technology, continue to shape the future of pharmaceutical science and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…